AMGEVITA

This brand name is authorized in Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug AMGEVITA contains one active pharmaceutical ingredient (API):

1	Adalimumab UNII FYS6T7F842 - ADALIMUMAB
	Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).
	Read more about Adalimumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AB04	Adalimumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10399H, 10400J, 10412B, 10413C, 10419J, 10420K, 10944B, 10955N, 10960W, 10961X, 12325Q, 12326R, 12327T, 12328W, 12329X, 12330Y, 12331B, 12332C, 12333D, 12334E, 12348X, 12349Y, 12350B, 12351C, 12352D, 12353E, 12354F, 12355G, 12356H, 12357J, 12365T, 12366W, 12367X, 12368Y, 12369B, 12370C, 12384T, 12385W, 12386X, 12387Y, 12388B, 12401Q, 12402R, 12403T, 12415K, 12416L, 12417M, 12420Q, 12434K, 12435L, 12436M, 12437N, 12438P, 12439Q, 12440R, 5281Y, 5282B, 5283C, 5284D, 8737W, 8741C, 8963R, 8964T, 8965W, 8966X, 9033K, 9034L, 9077R, 9078T, 9099X, 9100Y, 9101B, 9102C, 9103D, 9104E, 9188N, 9189P, 9190Q, 9191R, 9425C, 9426D, 9427E, 9428F, 9662M, 9663N, 9679K, 9680L
BR	Câmara de Regulação do Mercado de Medicamentos	544120010004307, 544120010004407, 544120010004507, 544120010004607, 544120010004707
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	14269065, 14269088, 14270200, 14270223, 15270567, 15270596, 15300788, 15307359, 15316973, 15316996, 15317004, 15317010, 15374114, 15374137, 15395464, 15395470, 15395487, 15395493, 15529232, 15529249, 15816032, 15816049, 15816055, 15816084, 15863095, 15863103, 15863132, 15863149, 15895853, 15895876, 16018338, 16018367, 16018373, 16018410, 16022848, 16022854, 16022860, 16022877, 17604386
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	147-MBE-1219
EE	Ravimiamet	1742239, 1742240, 1742251, 1742262, 1742273, 1742284, 1742295, 1742307, 1742318
ES	Centro de información online de medicamentos de la AEMPS	1161164001, 1161164002, 1161164006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	169691, 472938, 493438
FR	Base de données publique des médicaments	65407798, 66906448, 67080391
GB	Medicines & Healthcare Products Regulatory Agency	360050, 360052, 364357
HK	Department of Health Drug Office	66711, 66712
IE	Health Products Regulatory Authority	88950, 88951, 88952
IL	מִשְׂרַד הַבְּרִיאוּת	8972, 9433
LT	Valstybinė vaistų kontrolės tarnyba	1082605, 1082606, 1082607, 1082608, 1082609, 1082610, 1082611, 1082612, 1082613
NL	Z-Index G-Standaard, PRK	106348, 167207, 84492
NZ	Medicines and Medical Devices Safety Authority	20040, 20041, 20594
PL	Rejestru Produktów Leczniczych	100386775, 100386806
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65083001, W69244001
SG	Health Sciences Authority	15731P, 15732P, 15760P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699862950190, 8699862950206, 8699862950213, 8699862950220, 8699862950237